| scholarly article | Q13442814 |
| P50 | author | Nora G. Singer | Q37830320 |
| Chester V. Oddis | Q114404222 | ||
| P2093 | author name string | Clifton O Bingham | |
| Nancy E Lane | |||
| Dorothy D Dunlop | |||
| Daniel O Clegg | |||
| Allen D Sawitzke | |||
| Fred Wolfe | |||
| Domenic J Reda | |||
| Daniel E Furst | |||
| Helen Shi | |||
| Roland W Moskowitz | |||
| Jeffrey Lisse | |||
| David Silver | |||
| H James Williams | |||
| John D Bradley | |||
| Crystal L Harris | |||
| Christopher G Jackson | |||
| Martha F Finco | |||
| P2860 | cites work | EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: Report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT) | Q24674132 |
| Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis | Q28374250 | ||
| Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II | Q28396036 | ||
| Radiological assessment of osteo-arthrosis | Q29614927 | ||
| OsiriX: an open-source software for navigating in multidimensional DICOM images | Q31126270 | ||
| Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial | Q32050561 | ||
| A 2 yr longitudinal radiographic study examining the effect of a bisphosphonate (risedronate) upon subchondral bone loss in osteoarthritic knee patients | Q33249982 | ||
| Osteoarthritis: new insights. Part 1: the disease and its risk factors. | Q33921631 | ||
| Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis | Q33993736 | ||
| Structural and symptomatic efficacy of glucosamine and chondroitin in knee osteoarthritis: a comprehensive meta-analysis | Q34214244 | ||
| Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study | Q34528067 | ||
| Meta-analysis: chondroitin for osteoarthritis of the knee or hip. | Q34619761 | ||
| Which is the best radiographic protocol for a clinical trial of a structure modifying drug in patients with knee osteoarthritis? | Q34685925 | ||
| Comparison of quantitative and semiquantitative indicators of joint space narrowing in subjects with knee osteoarthritis | Q35636580 | ||
| Review of the anatomical and radiological differences between fluoroscopic and non-fluoroscopic positioning of osteoarthritic knees | Q36511560 | ||
| Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthri | Q39344079 | ||
| Measurement of radiographic joint space width in the tibiofemoral compartment of the osteoarthritic knee: comparison of standing anteroposterior and Lyon schuss views | Q39641539 | ||
| Detection of radiographic joint space narrowing in subjects with knee osteoarthritis: longitudinal comparison of the metatarsophalangeal and semiflexed anteroposterior views | Q39641542 | ||
| Pitfalls in the accurate measurement of joint space narrowing in semiflexed, anteroposterior radiographic imaging of the knee | Q39693235 | ||
| Effect of non-steroidal anti-inflammatory drugs on the course of osteoarthritis | Q41277159 | ||
| Early stages of osteoarthritis: the search for sensitive predictors | Q42118121 | ||
| Yet more evidence that osteoarthritis is not a cartilage disease | Q42955504 | ||
| Variability in knee radiographing: implication for definition of radiological progression in medial knee osteoarthritis. | Q43053545 | ||
| Effect sizes for interpreting changes in health status. | Q43872888 | ||
| A 12-month, multicenter, prospective, open-label trial of radiographic analysis of disease progression in osteoarthritis of the knee or hip in patients receiving celecoxib | Q44311938 | ||
| OMERACT workshop radiography session 1. | Q46453352 | ||
| Radiographic methods in knee osteoarthritis: a further comparison of semiflexed (MTP), schuss-tunnel, and weight-bearing anteroposterior views for joint space narrowing and osteophytes. | Q47174826 | ||
| Reproducibility of the semiflexed (metatarsophalangeal) radiographic knee position and automated measurements of medial tibiofemoral joint space width in a multicenter clinical trial of knee osteoarthritis. | Q48563818 | ||
| Effects of oral chondroitin sulfate on the progression of knee osteoarthritis: a pilot study | Q48592216 | ||
| Guidelines for testing slow acting drugs in osteoarthritis. | Q50597580 | ||
| Selection of knee radiographs for trials of structure-modifying drugs in patients with knee osteoarthritis: a prospective, longitudinal study of Lyon Schuss knee radiographs with the definition of adequate alignment of the medial tibial plateau | Q50761045 | ||
| Precision and accuracy of joint space width measurements of the medial compartment of the knee using standardized MTP semi-flexed radiographs. | Q51824157 | ||
| Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. | Q55047291 | ||
| Assessment of the radioanatomic positioning of the osteoarthritic knee in serial radiographs: comparison of three acquisition techniques | Q56420434 | ||
| The association of meniscal pathologic changes with cartilage loss in symptomatic knee osteoarthritis | Q57244856 | ||
| The relationship between cartilage loss on magnetic resonance imaging and radiographic progression in men and women with knee osteoarthritis | Q57244861 | ||
| Comparison of naproxen and acetaminophen in a two-year study of treatment of osteoarthritis of the knee | Q72547388 | ||
| Substantial superiority of semiflexed (MTP) views in knee osteoarthritis: a comparative radiographic study, without fluoroscopy, of standing extended, semiflexed (MTP), and schuss views | Q73292593 | ||
| Field test of the reproducibility of the semiflexed metatarsophalangeal view in repeated radiographic examinations of subjects with osteoarthritis of the knee | Q77567369 | ||
| [Anti-arthrosis treatments: efficacy and tolerance of chondroitin sulfates (CS 4&6)] | Q77693001 | ||
| Chondroitins 4 and 6 sulfate in osteoarthritis of the knee: a randomized, controlled trial | Q81484755 | ||
| Translating osteoarthritis into numbers: the importance of alignment in knee radiography for clinical trials of structure-modifying drugs | Q81726566 | ||
| Comparison of fixed flexion, fluoroscopic semi-flexed and MTP radiographic methods for obtaining the minimum medial joint space width of the knee in longitudinal osteoarthritis trials | Q83309519 | ||
| Efficacy of glucosamine and chondroitin for treatment of osteoarthritis | Q93939295 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | knee osteoarthritis | Q1777118 |
| osteoarthritis | Q62736 | ||
| glucosamine | Q32907954 | ||
| P304 | page(s) | 3183-3191 | |
| P577 | publication date | 2008-10-01 | |
| P1433 | published in | Arthritis and Rheumatism | Q23929027 |
| P1476 | title | The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial | |
| P478 | volume | 58 |
| Q33678954 | 10mM glucosamine prevents activation of proADAMTS5 (aggrecanase-2) in transfected cells by interference with post-translational modification of furin |
| Q42697105 | A Fresh Perspective on a Familiar Problem: Examining Disparities in Knee Osteoarthritis Using a Markov Model |
| Q33873693 | A peptidyl-glucosamine derivative affects IKKalpha kinase activity in human chondrocytes |
| Q35770645 | A randomized comparative study of safety and efficacy of immediate release glucosamine HCL and glucosamine HCL sustained release formulation in the treatment of knee osteoarthritis: A proof of concept study |
| Q39906208 | Anticytokine therapy for osteoarthritis: evidence to date |
| Q89851444 | Arctigenin prevents the progression of osteoarthritis by targeting PI3K/Akt/NF-κB axis: In vitro and in vivo studies |
| Q90695739 | Association of Pharmacological Treatments With Long-term Pain Control in Patients With Knee Osteoarthritis: A Systematic Review and Meta-analysis |
| Q38429953 | COX-2-selective NSAIDs and risk of hip or knee replacements: a population-based case-control study |
| Q35197151 | Can we identify patients with high risk of osteoarthritis progression who will respond to treatment? A focus on epidemiology and phenotype of osteoarthritis |
| Q37960493 | Cartilage repair and joint preservation: medical and surgical treatment options |
| Q35840709 | Celecoxib: considerations regarding its potential disease-modifying properties in osteoarthritis |
| Q24186473 | Chondroitin for osteoarthritis |
| Q36059429 | Chondroitin sulfate in the treatment of osteoarthritis: from in vitro studies to clinical recommendations. |
| Q34906145 | Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI |
| Q99709180 | Chondroprotective Actions of Selective COX-2 Inhibitors In Vivo: A Systematic Review |
| Q24602794 | Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT |
| Q39539742 | Combined Treatment With Chondroitin Sulfate and Glucosamine Sulfate Shows No Superiority Over Placebo for Reduction of Joint Pain and Functional Impairment in Patients With Knee Osteoarthritis: A Six-Month Multicenter, Randomized, Double-Blind, Plac |
| Q34188301 | Comparative therapeutic efficacy and safety of type-II collagen (UC-II), glucosamine and chondroitin in arthritic dogs: pain evaluation by ground force plate |
| Q24630640 | Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic properties |
| Q36059344 | Current evidence for osteoarthritis treatments |
| Q47570656 | Current status and future prospects for disease modification in osteoarthritis. |
| Q43076770 | Dietary glucosamine under question |
| Q33920880 | Dietary supplements as disease-modifying treatments in osteoarthritis: a critical appraisal |
| Q30588700 | Disease-modifying osteoarthritis drugs: in vitro and in vivo data on the development of DMOADs under investigation. |
| Q50459670 | Effect of oral glucosamine on joint structure in individuals with chronic knee pain: a randomized, placebo-controlled clinical trial |
| Q35147261 | Effects of Glucosamine and Chondroitin Sulfate on Cartilage Metabolism in OA: Outlook on Other Nutrient Partners Especially Omega-3 Fatty Acids |
| Q35125975 | Effects of glucosamine and chondroitin supplementation on knee osteoarthritis: an analysis with marginal structural models |
| Q24606203 | Effects of glucosamine, chondroitin, or placebo in patients with osteoarthritis of hip or knee: network meta-analysis |
| Q34345032 | Efficacies of different preparations of glucosamine for the treatment of osteoarthritis: a meta-analysis of randomised, double-blind, placebo-controlled trials |
| Q28081360 | Efficacy and safety of glucosamine, diacerein, and NSAIDs in osteoarthritis knee: a systematic review and network meta-analysis |
| Q28278433 | Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial |
| Q36247005 | Efficacy of pulsed Nd:YAG laser in the treatment of patients with knee osteoarthritis: a randomized controlled trial. |
| Q38758657 | Feline hip dysplasia: A challenge to recognise and treat. |
| Q30714596 | First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort |
| Q37645550 | FlexPro MD, a Mixture of Krill Oil, Astaxanthin, and Hyaluronic Acid, Suppresses Lipopolysaccharide-Induced Inflammatory Cytokine Production Through Inhibition of NF-κB. |
| Q38090916 | Functional articular cartilage repair: here, near, or is the best approach not yet clear? |
| Q38362244 | Glucosamine Hydrochloride but Not Chondroitin Sulfate Prevents Cartilage Degradation and Inflammation Induced by Interleukin-1α in Bovine Cartilage Explants |
| Q34396147 | Glucosamine and chondroitin for knee osteoarthritis: a double-blind randomised placebo-controlled clinical trial evaluating single and combination regimens |
| Q42330053 | Glucosamine and chondroitin for the treatment of osteoarthritis |
| Q41176136 | Glucosamine exposure reduces proteoglycan synthesis in primary human endothelial cells in vitro |
| Q24630093 | Hepatotoxicity associated with glucosamine and chondroitin sulfate in patients with chronic liver disease |
| Q36949072 | How to define responders in osteoarthritis |
| Q35006721 | How to find nothing |
| Q46189093 | Identifying common trajectories of joint space narrowing over two years in knee osteoarthritis |
| Q34069452 | Immune modulation by chondroitin sulfate and its degraded disaccharide product in the development of an experimental model of multiple sclerosis |
| Q44118071 | Importance of pharmaceutical composition and evidence from clinical trials and pharmacological studies in determining effectiveness of chondroitin sulphate and other glycosaminoglycans: a critique |
| Q21195259 | Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis? |
| Q37164156 | Knee osteoarthritis diagnosis, treatment and associated factors of progression: part II. |
| Q31046250 | Long-Term Effects of Glucosamine and Chondroitin Sulfate on the Progression of Structural Changes in Knee Osteoarthritis: Six-Year Followup Data From the Osteoarthritis Initiative |
| Q34459643 | Management of Osteoarthritis with Avocado/Soybean Unsaponifiables. |
| Q35678484 | Methodologic issues in clinical trials for prevention or risk reduction in osteoarthritis |
| Q37798321 | Modern Management of Mild-to-Moderate Joint Pain due to Osteoarthritis: A Holistic Approach |
| Q38212443 | Modified lysozymes as novel broad spectrum natural antimicrobial agents in foods |
| Q37950849 | Non-surgical management of early knee osteoarthritis |
| Q38797713 | Non-surgical treatments for the management of early osteoarthritis. |
| Q38047227 | Nutraceuticals in the management of osteoarthritis : a critical review |
| Q34146992 | Nutraceuticals: do they represent a new era in the management of osteoarthritis? – a narrative review from the lessons taken with five products |
| Q26860861 | Nutraceuticals: potential for chondroprotection and molecular targeting of osteoarthritis |
| Q42683780 | OARSI-OMERACT initiative: defining thresholds for symptomatic severity and structural changes in disease modifying osteoarthritis drug (DMOAD) clinical trials |
| Q64062465 | Osteoarthritis- a systematic review of long-term safety implications for osteoarthritis of the knee |
| Q60959033 | Pharmacological treatment of knee osteoarthritis: Special considerations of the new German guideline |
| Q33845330 | Press releases issued by supplements industry organisations and non-industry organisations in response to publication of clinical research findings: a case-control study. |
| Q34157463 | Progress in complementary and alternative medicine research: Yale Research Symposium on Complementary and Integrative Medicine |
| Q37611121 | Quality of different chondroitin sulfate preparations in relation to their therapeutic activity |
| Q26799421 | Recommendations for an update of the 2010 European regulatory guideline on clinical investigation of medicinal products used in the treatment of osteoarthritis and reflections about related clinically relevant outcomes: expert consensus statement |
| Q33752290 | Relationship between radiographic changes and symptoms or physical examination findings in subjects with symptomatic medial knee osteoarthritis: a three-year prospective study |
| Q34264613 | Role of glucosamine in the treatment for osteoarthritis |
| Q39044794 | Suppressive effects of D-glucosamine on the 5-HT sensitive nociceptive units in the rat tooth pulpal nerve |
| Q41966032 | The Fate of Oral Glucosamine Traced by (13)C Labeling in the Dog. |
| Q45969369 | The glucosamine debate: is it better than placebo? |
| Q47101159 | Therapeutic Effects of Olive and Its Derivatives on Osteoarthritis: From Bench to Bedside |
| Q37964507 | Transglutaminase 2 as a biomarker of osteoarthritis: an update. |
| Q34605944 | Transglutaminase 2 is a marker of chondrocyte hypertrophy and osteoarthritis severity in the Hartley guinea pig model of knee OA. |
| Q37858371 | Treatment options for osteoarthritis: considerations for older adults |
| Q37868775 | What about supplements for osteoarthritis? A critical and evidenced-based review |
Search more.